Quarterly ResultMay 13, 2026, 04:32 PM
Vivani Medical Q1 Net Loss $6.8M; SLIM-1 Trial On Track Mid-2026
AI Summary
Vivani Medical reported a net loss of $6.8 million for the first quarter ended March 31, 2026, an increase from $6.3 million in the prior year. The company announced it is on track to initiate its SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant for chronic weight management, by mid-2026, with top-line results expected by year-end. Vivani Medical also stated it has $28 million in cash and capital commitments, providing a runway to fund operations through the first half of 2027, and continues to explore options for its Cortigent neuromodulation assets.
Key Highlights
- Vivani Medical reported a Q1 2026 net loss of $6.8 million, compared to $6.3 million in Q1 2025.
- Cash, cash equivalents, restricted cash, and capital commitments total $28 million, funding operations through H1 2027.
- Research and development expense, net of grants, increased 4% to $4.4 million in Q1 2026.
- General and administrative expense, net of grants, increased 4% to $2.4 million in Q1 2026.
- Cash used in operating activities was $6.2 million during Q1 2026.
- Cash provided by financing activities was $9.7 million during Q1 2026.
- Initiation of SLIM-1 Phase 1 clinical trial for NPM-139 on track for mid-2026, with top-line results by end of 2026.
- Cortigent Inc., a wholly owned subsidiary, filed an amended Form S-1 for its transition to an independent public company.
Price Impact
More from VANI